TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04127721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO
Study: NCT03383926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6cm suture
Description: Suture confection of the Tobacco-pouch of 6cm from the anal margin.
Study: NCT01332773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery first procedure
Description: early identification of SMA to evaluate infiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No artery first procedure
Description: conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
Study: NCT01940185

Intervention type: DEVICE
Intervention: LINX device
Study: NCT04127721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT03399058

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1 5+5+5 (Control)
Description: The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 2: 5+5+5 & PDH
Description: The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 3: 5+5+5 & PDH lite+mHealth
Description: The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
Study: NCT03267368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Care Program
Description: Pulmonary rehabilitation and smoking cessation
Study: NCT00333775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to bevacizumab
Description: Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
Study: NCT00364676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLI
Description: Patients are dosed on Day 1 and Day 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLI
Description: Patients are dosed on Day 1 of a 21-day cycle.
Study: NCT01706172

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 20% dextrose/ 0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
Study: NCT01415882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01745926

Intervention type: DEVICE
Intervention: MECHANICAL CHEST COMPRESSION
Study: NCT02110563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-MYC
Description: Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT01838317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study: NCT04350281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1B
Description: Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
Study: NCT04262700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeScan's new BGMS
Description: LifeScan new Blood Glucose Monitoring System (BGMS)
Study: NCT01460966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filtrap™ + Thrombus aspiration catheter
Description: Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration catheter
Description: Thrombus aspiration catheter only
Study: NCT02121379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Study: NCT04199507

Intervention type: OTHER
Intervention: physical fitness assessment
Description: assessment

Intervention type: OTHER
Intervention: physical fitness assessment
Description: assessment
Study: NCT04368260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control swab
Description: FDA-cleared nasopharyngeal swab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype swab
Description: Injection molded polypropylene flocked nylon nasopharyngeal swab
Study: NCT02906423

Intervention type: OTHER
Intervention: PROMIS-10 questionnaire
Description: Patient completed a PROMIS-10 questionnaire
Study: NCT02232035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline/diazepam at the active phase of labor
Description: A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline/diazepam at the active phase of labor
Description: A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
Study: NCT01009658

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monosodium glutamate
Description: Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
Study: NCT02760615

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: Caffeine tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: Caffeine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: Losartan tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: Losartan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Omeprazole capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Omeprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam syrup

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup

Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab
Description: Vedolizumab solution for IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab
Description: Vedolizumab solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab solution for IV infusion
Study: NCT01274026

Intervention type: DRUG
Intervention: sapropterin dihydrochloride
Description: In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.
Study: NCT00734435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zonisamide SR plus olanzapine
Description: zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus olanzapine
Description: Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
Study: NCT00961311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprinter Legend 1.25mm Balloon Catheter
Description: Balloon Angioplasty
Study: NCT02028923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine gel
Description: Topical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral gel
Description: Topical
Study: NCT02571114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saskatoon Berry Frozen Yogurt
Description: Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Frozen Yogurt
Description: Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: White bread (serving size = 25 g available carbohydrate)
Study: NCT03744104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 0.5 mL, intramuscular, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine A
Description: 0.5 mL, intramuscular, one dose
Study: NCT02571114

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control 2
Description: White bread (serving size = 25 g available carbohydrate)
Study: NCT03223402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nevirapine plus lamivudine
Description: In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
Study: NCT03093896

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: snack mix
Description: commercial cereal mix with bits of beef jerky and coconut

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds, 1.5 oz
Description: almonds, 1.5 oz/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: almonds, 3 oz
Description: almonds, 3.0 oz/day
Study: NCT02212808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial restriction
Description: All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-antimicrobial prescription review
Description: All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
Study: NCT01216202

Intervention type: RADIATION
Intervention: Preoperative radiotherapy
Description: Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes.
Study: NCT02246725

Intervention type: OTHER
Intervention: Contact with palliative care unit.
Study: NCT02967146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adhesive barrier
Description: After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
Study: NCT02519439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: 225 mg capsules 450 mg to 900 mg 2x/day
Study: NCT00230126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
Study: NCT00434226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25 mg/day for 2 weeks, followed by 1 week of rest

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: On the first day of each cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: On the first day of each cycle for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: On the first day of each cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: On the first day of each cycle for 4 cycles
Study: NCT03287401

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Patients electroencephalogram will be recorded
Study: NCT03901495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaana
Description: Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals.
Study: NCT02223780

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: early palliative care
Description: the patients will benefit from an early palliative care consultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early palliative care
Description: the patients will benefit from an early palliative care consultation
Study: NCT03121859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IFC
Description: Interferential current therapy(IFC)
Study: NCT03476200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
Study: NCT04103359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological tests to measure fatigue level
Description: Physiological tests to measure fatigue level
Study: NCT01329302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration
Description: In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration
Description: In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
Study: NCT02367508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MODEL Care
Description: The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.